Drugmaker Sanofi hungry for deals after earnings beat

French drugmaker Sanofi stepped up its overhaul on Friday, putting its European generic drugs business up for sale and saying that a planned 3.5 billion euro (3 billion pounds) share buyback would not suppress its appetite for deals. Sanofi's announcement came as it posted better than expected earnings and lifted its profit guidance for the year on strong growth at its biotech arm Genzyme and an early start to the U.S. flu vaccine season. Sanofi now expects 2016 adjusted earnings per share to gr